



Nicox added to Russell Global Index

June 27, 2016

Sophia Antipolis, France.

Nicox S.A. (Euronext Paris: FR0000074130, COX), the international ophthalmic company, today announced that it was added to the Russell Global Index when the Russell Investment Group reconstituted its family of U.S. indexes effective today, June 27, 2016.

Membership in the Russell Global Index, which remains in place for one year, means automatic inclusion in the appropriate large-cap, small-cap, all-cap indexes as well as the applicable style, sector and country indexes. FTSE Russell determines membership for its Russell indexes by objective, market-capitalization rankings and style attributes.

Indexes provided by FTSE Russell, a leading global index provider, are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies.

For more information on the Russell Global Index and the Russell US Indexes and Russell Global Indexes reconstitution, go to the “Russell Reconstitution” section on the [FTSE Russell website](#).

About Nicox

Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is an international commercial-stage company focused on the ophthalmic market. With a heritage of innovative R&D, business development, and marketing expertise, Nicox is building a diversified portfolio of ophthalmic products that can help people enhance their sight.

Nicox’s advanced pipeline features latanoprostene bunod for the lowering of intra-ocular pressure (IOP) in patients with open angle glaucoma or ocular hypertension, for which a New Drug Application (NDA) was submitted to the FDA by the Company’s licensee Bausch + Lomb, Valeant Pharmaceuticals International, Inc.’s, wholly owned subsidiary. The Company’s pipeline also features AC-170, for which the FDA granted priority review for the NDA for the treatment of ocular itching associated with allergic conjunctivitis as well as two pre-MAA candidates in Europe: AzaSite® for bacterial conjunctivitis and BromSite™ for pain and inflammation after cataract surgery. Beyond these late-stage candidates, Nicox is developing a pipeline of next generation ophthalmology-focused candidates, which utilize its proprietary nitric oxide (NO)-donating research platform. The Group has operations in Europe and the United States.

Nicox is listed on Euronext Paris (Category B: Mid Caps) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes. For more information on Nicox, its commercial products or pipeline, please visit: www.nicox.com.

Analyst coverage

Bryan, Garnier & Co	Hugo Solvet	Paris, France
Invest Securities	Martial Descoutures	Paris, France
Gilbert Dupont	Damien Choplain	Paris, France



Upcoming 2016 events

Financial and business conferences

June 28	SGCIB Healthcare & Biotechnology conference	Paris, France
July 12-13	Cantor Fitzgerald's 2 nd Annual Healthcare conference	New York, US
September 11-13	Rodman & Renshaw Annual Global Investment conference	New York, US
October 5-6	Large et Midcap Event	Paris, France

.....

Contacts

Nicox **Gavin Spencer** | Executive Vice President Corporate Development
Tel +33 (0)4 97 24 53 00 | communications@nicox.com

Media Relations

United Kingdom **Jonathan Birt**
Tel +44 7860 361 746 | jonathan.birt@ymail.com

France **NewCap** | Nicolas Merigeau
Tel +33 (0)1 44 71 94 98 | nicox@newcap.eu

United States **Argot Partners** | Eliza Schleifstein
Tel +1 (917) 763-8106 | eliza@argotpartners.com

Investor Relations

Europe **NewCap** | Julien Perez | Valentine Brouchet
Tel +33 (0)1 44 71 94 94 | nicox@newcap.eu

United States **Argot Partners** | Melissa Forst
Tel +1 (212) 600-1902 | melissa@argotpartners.com

.....

This press release contains certain forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements.

Risks factors which are likely to have a material effect on Nicox's business are presented in the 4th chapter of the 'Document de référence, rapport financier annuel et rapport de gestion 2015' filed with the French *Autorité des Marchés Financiers* (AMF) on April 15, 2016, which is available on Nicox's website (www.nicox.com).